Prevention of sudden death in patients with coronary artery disease

The multicenter unsustained tachycardia trial (MUSTT)

Alfred E. Buxton, John Devens Fisher, Mark E. Josephson, Kerry L. Lee, David B. Pryor, Eric N. Prystowsky, Michael B. Simson, Lorenzo DiCarlo, Debra S. Echt, Douglas Packer, G. Stephen Greer, Mario Talajic, MUSTT Investigators the MUSTT Investigators

Research output: Contribution to journalArticle

127 Citations (Scopus)

Abstract

This trial will significantly advance our understanding of the prognostic and therapeutic usefulness of electrophysiologic studies in patients with coronary artery disease. Several features of this trial are worth emphasizing. First, the protocol for performing programmed stimulation and serial drug testing is designed to mirror those currently in use by many practicing electrophysiologists. While practice patterns vary, the procedures used in the trial reflect what is considered "usual and standard" practice. Second, because half of the patients with inducible sustained ventricular tachycardia will be given no antiarrhythmic therapy, we will be able to ascertain the true risk of sudden death in this patient population without the influence of these agents. Third, this trial will assess the usefulness of a method of guiding antiarrhythmic therapy (electrophysiologic testing) to reduce mortality in this high-risk population. It will not evaluate the efficacy of a specific type of antiarrhythmic therapy.

Original languageEnglish (US)
Pages (from-to)215-226
Number of pages12
JournalProgress in Cardiovascular Diseases
Volume36
Issue number3
DOIs
StatePublished - 1993
Externally publishedYes

Fingerprint

Sudden Death
Tachycardia
Coronary Artery Disease
Therapeutics
Ventricular Tachycardia
Population
Mortality
Pharmaceutical Preparations

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine

Cite this

Buxton, A. E., Fisher, J. D., Josephson, M. E., Lee, K. L., Pryor, D. B., Prystowsky, E. N., ... the MUSTT Investigators, MUSTT. I. (1993). Prevention of sudden death in patients with coronary artery disease: The multicenter unsustained tachycardia trial (MUSTT). Progress in Cardiovascular Diseases, 36(3), 215-226. https://doi.org/10.1016/0033-0620(93)90015-6

Prevention of sudden death in patients with coronary artery disease : The multicenter unsustained tachycardia trial (MUSTT). / Buxton, Alfred E.; Fisher, John Devens; Josephson, Mark E.; Lee, Kerry L.; Pryor, David B.; Prystowsky, Eric N.; Simson, Michael B.; DiCarlo, Lorenzo; Echt, Debra S.; Packer, Douglas; Stephen Greer, G.; Talajic, Mario; the MUSTT Investigators, MUSTT Investigators.

In: Progress in Cardiovascular Diseases, Vol. 36, No. 3, 1993, p. 215-226.

Research output: Contribution to journalArticle

Buxton, AE, Fisher, JD, Josephson, ME, Lee, KL, Pryor, DB, Prystowsky, EN, Simson, MB, DiCarlo, L, Echt, DS, Packer, D, Stephen Greer, G, Talajic, M & the MUSTT Investigators, MUSTTI 1993, 'Prevention of sudden death in patients with coronary artery disease: The multicenter unsustained tachycardia trial (MUSTT)', Progress in Cardiovascular Diseases, vol. 36, no. 3, pp. 215-226. https://doi.org/10.1016/0033-0620(93)90015-6
Buxton, Alfred E. ; Fisher, John Devens ; Josephson, Mark E. ; Lee, Kerry L. ; Pryor, David B. ; Prystowsky, Eric N. ; Simson, Michael B. ; DiCarlo, Lorenzo ; Echt, Debra S. ; Packer, Douglas ; Stephen Greer, G. ; Talajic, Mario ; the MUSTT Investigators, MUSTT Investigators. / Prevention of sudden death in patients with coronary artery disease : The multicenter unsustained tachycardia trial (MUSTT). In: Progress in Cardiovascular Diseases. 1993 ; Vol. 36, No. 3. pp. 215-226.
@article{20219387a0204519bb77d23eaa8ba6a7,
title = "Prevention of sudden death in patients with coronary artery disease: The multicenter unsustained tachycardia trial (MUSTT)",
abstract = "This trial will significantly advance our understanding of the prognostic and therapeutic usefulness of electrophysiologic studies in patients with coronary artery disease. Several features of this trial are worth emphasizing. First, the protocol for performing programmed stimulation and serial drug testing is designed to mirror those currently in use by many practicing electrophysiologists. While practice patterns vary, the procedures used in the trial reflect what is considered {"}usual and standard{"} practice. Second, because half of the patients with inducible sustained ventricular tachycardia will be given no antiarrhythmic therapy, we will be able to ascertain the true risk of sudden death in this patient population without the influence of these agents. Third, this trial will assess the usefulness of a method of guiding antiarrhythmic therapy (electrophysiologic testing) to reduce mortality in this high-risk population. It will not evaluate the efficacy of a specific type of antiarrhythmic therapy.",
author = "Buxton, {Alfred E.} and Fisher, {John Devens} and Josephson, {Mark E.} and Lee, {Kerry L.} and Pryor, {David B.} and Prystowsky, {Eric N.} and Simson, {Michael B.} and Lorenzo DiCarlo and Echt, {Debra S.} and Douglas Packer and {Stephen Greer}, G. and Mario Talajic and {the MUSTT Investigators}, {MUSTT Investigators}",
year = "1993",
doi = "10.1016/0033-0620(93)90015-6",
language = "English (US)",
volume = "36",
pages = "215--226",
journal = "Progress in Cardiovascular Diseases",
issn = "0033-0620",
publisher = "W.B. Saunders Ltd",
number = "3",

}

TY - JOUR

T1 - Prevention of sudden death in patients with coronary artery disease

T2 - The multicenter unsustained tachycardia trial (MUSTT)

AU - Buxton, Alfred E.

AU - Fisher, John Devens

AU - Josephson, Mark E.

AU - Lee, Kerry L.

AU - Pryor, David B.

AU - Prystowsky, Eric N.

AU - Simson, Michael B.

AU - DiCarlo, Lorenzo

AU - Echt, Debra S.

AU - Packer, Douglas

AU - Stephen Greer, G.

AU - Talajic, Mario

AU - the MUSTT Investigators, MUSTT Investigators

PY - 1993

Y1 - 1993

N2 - This trial will significantly advance our understanding of the prognostic and therapeutic usefulness of electrophysiologic studies in patients with coronary artery disease. Several features of this trial are worth emphasizing. First, the protocol for performing programmed stimulation and serial drug testing is designed to mirror those currently in use by many practicing electrophysiologists. While practice patterns vary, the procedures used in the trial reflect what is considered "usual and standard" practice. Second, because half of the patients with inducible sustained ventricular tachycardia will be given no antiarrhythmic therapy, we will be able to ascertain the true risk of sudden death in this patient population without the influence of these agents. Third, this trial will assess the usefulness of a method of guiding antiarrhythmic therapy (electrophysiologic testing) to reduce mortality in this high-risk population. It will not evaluate the efficacy of a specific type of antiarrhythmic therapy.

AB - This trial will significantly advance our understanding of the prognostic and therapeutic usefulness of electrophysiologic studies in patients with coronary artery disease. Several features of this trial are worth emphasizing. First, the protocol for performing programmed stimulation and serial drug testing is designed to mirror those currently in use by many practicing electrophysiologists. While practice patterns vary, the procedures used in the trial reflect what is considered "usual and standard" practice. Second, because half of the patients with inducible sustained ventricular tachycardia will be given no antiarrhythmic therapy, we will be able to ascertain the true risk of sudden death in this patient population without the influence of these agents. Third, this trial will assess the usefulness of a method of guiding antiarrhythmic therapy (electrophysiologic testing) to reduce mortality in this high-risk population. It will not evaluate the efficacy of a specific type of antiarrhythmic therapy.

UR - http://www.scopus.com/inward/record.url?scp=0027370617&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0027370617&partnerID=8YFLogxK

U2 - 10.1016/0033-0620(93)90015-6

DO - 10.1016/0033-0620(93)90015-6

M3 - Article

VL - 36

SP - 215

EP - 226

JO - Progress in Cardiovascular Diseases

JF - Progress in Cardiovascular Diseases

SN - 0033-0620

IS - 3

ER -